GSK (LON:GSK) Rating Reiterated by Deutsche Bank Aktiengesellschaft

GSK (LON:GSK)‘s stock had its “buy” rating restated by equities researchers at Deutsche Bank Aktiengesellschaft in a report issued on Friday, MarketBeat.com reports. They currently have a GBX 1,950 ($24.74) price objective on the stock. Deutsche Bank Aktiengesellschaft’s target price points to a potential upside of 27.49% from the stock’s current price.

Several other equities analysts have also recently weighed in on GSK. Citigroup restated a “buy” rating and set a GBX 2,100 ($26.64) price objective on shares of GSK in a research note on Monday, June 24th. JPMorgan Chase & Co. restated an “underweight” rating on shares of GSK in a report on Tuesday, June 18th. Barclays reiterated an “equal weight” rating and issued a GBX 1,725 ($21.88) price objective on shares of GSK in a research note on Tuesday, May 7th. Shore Capital restated a “buy” rating on shares of GSK in a research note on Thursday. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 2,100 ($26.64) price target on shares of GSK in a research report on Thursday. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of GBX 1,791.25 ($22.72).

GSK Stock Performance

Shares of GSK stock opened at GBX 1,529.50 ($19.40) on Friday. GSK has a 52 week low of GBX 1,302.60 ($16.52) and a 52 week high of GBX 1,823.50 ($23.13). The company has a quick ratio of 0.73, a current ratio of 0.87 and a debt-to-equity ratio of 134.34. The business has a 50 day moving average price of GBX 1,685.84 and a 200-day moving average price of GBX 1,631.05. The company has a market cap of £62.40 billion, a PE ratio of 1,403.21, a price-to-earnings-growth ratio of 1.19 and a beta of 0.27.

Insiders Place Their Bets

In other news, insider Wendy Becker acquired 446 shares of the stock in a transaction that occurred on Thursday, June 20th. The shares were acquired at an average cost of GBX 1,614 ($20.47) per share, for a total transaction of £7,198.44 ($9,131.60). Company insiders own 1.60% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.